This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Correction

Correction

Jennifer Swainson, MD; and Atul Khullar, MD, MSc

Published: April 22, 2020

Correction

In the letter "Sublingual Ketamine: An Option for Increasing Accessibility of Ketamine Treatments for Depression?" by Jennifer Swainson, MD, and Atul Khullar, MD, MSc, published in the January/February 2020 issue (J Clin Psychiatry 2020;81[1]:19lr13146), conflict of interest information has been corrected to show that Dr Swainson has been on advisory boards for, received speaker honoraria from, and provided consultancy services to Lundbeck, Otsuka, Sunovion, and Janssen, and Dr Khullar has been on advisory boards for, received speaker honoraria from, and provided consultancy services to Lundbeck, Otsuka, Sunovion, Janssen, Shire, Bausch, Takeda, and Eisai.

Volume: 81

Quick Links: Depression (MDD)

References

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or...

Read More...